• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膜融合后登革病毒包膜蛋白的结构。

Structure of the dengue virus envelope protein after membrane fusion.

作者信息

Modis Yorgo, Ogata Steven, Clements David, Harrison Stephen C

机构信息

Howard Hughes Medical Institute, Children's Hospital and Harvard Medical School, 320 Longwood Avenue, Boston, Massachusetts 02115, USA.

出版信息

Nature. 2004 Jan 22;427(6972):313-9. doi: 10.1038/nature02165.

DOI:10.1038/nature02165
PMID:14737159
Abstract

Dengue virus enters a host cell when the viral envelope glycoprotein, E, binds to a receptor and responds by conformational rearrangement to the reduced pH of an endosome. The conformational change induces fusion of viral and host-cell membranes. A three-dimensional structure of the soluble E ectodomain (sE) in its trimeric, postfusion state reveals striking differences from the dimeric, prefusion form. The elongated trimer bears three 'fusion loops' at one end, to insert into the host-cell membrane. Their structure allows us to model directly how these fusion loops interact with a lipid bilayer. The protein folds back on itself, directing its carboxy terminus towards the fusion loops. We propose a fusion mechanism driven by essentially irreversible conformational changes in E and facilitated by fusion-loop insertion into the outer bilayer leaflet. Specific features of the folded-back structure suggest strategies for inhibiting flavivirus entry.

摘要

当病毒包膜糖蛋白E与受体结合并因内体pH值降低而发生构象重排时,登革病毒进入宿主细胞。这种构象变化诱导病毒膜与宿主细胞膜融合。处于三聚体、融合后状态的可溶性E胞外域(sE)的三维结构显示出与二聚体、融合前形式的显著差异。细长的三聚体一端有三个“融合环”,可插入宿主细胞膜。它们的结构使我们能够直接模拟这些融合环如何与脂质双层相互作用。蛋白质自身折叠,将其羧基末端指向融合环。我们提出了一种由E中基本不可逆的构象变化驱动、并由融合环插入外双层小叶促进的融合机制。折叠后结构的特定特征提示了抑制黄病毒进入的策略。

相似文献

1
Structure of the dengue virus envelope protein after membrane fusion.膜融合后登革病毒包膜蛋白的结构。
Nature. 2004 Jan 22;427(6972):313-9. doi: 10.1038/nature02165.
2
Structure of the immature dengue virus at low pH primes proteolytic maturation.低pH值下未成熟登革病毒的结构引发蛋白水解成熟。
Science. 2008 Mar 28;319(5871):1834-7. doi: 10.1126/science.1153264.
3
The flavivirus precursor membrane-envelope protein complex: structure and maturation.黄病毒前体膜包膜蛋白复合物:结构与成熟
Science. 2008 Mar 28;319(5871):1830-4. doi: 10.1126/science.1153263.
4
Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G.水泡性口炎病毒糖蛋白G的前融合形式的结构
Science. 2007 Feb 9;315(5813):843-8. doi: 10.1126/science.1135710.
5
Picture story. Does Dengue virus fuse using beta-barrels?图片故事。登革病毒是否通过β桶进行融合?
Nat Struct Biol. 2002 Apr;9(4):244. doi: 10.1038/nsb0402-244.
6
Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus.塞姆利基森林病毒融合蛋白的构象变化及蛋白质-蛋白质相互作用
Nature. 2004 Jan 22;427(6972):320-5. doi: 10.1038/nature02239.
7
Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion.1型登革病毒包膜蛋白融合后构象的晶体结构及其对膜融合的影响
J Virol. 2009 May;83(9):4338-44. doi: 10.1128/JVI.02574-08. Epub 2009 Feb 25.
8
Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G.水泡性口炎病毒糖蛋白G低pH值形式的晶体结构。
Science. 2006 Jul 14;313(5784):187-91. doi: 10.1126/science.1127683.
9
In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.利用登革热病毒包膜 E 蛋白对小分子文库进行计算机筛选,发现了具有抗多种黄病毒活性的化合物。
Antiviral Res. 2009 Dec;84(3):234-41. doi: 10.1016/j.antiviral.2009.09.007. Epub 2009 Sep 23.
10
Conformational changes in Sindbis virions resulting from exposure to low pH and interactions with cells suggest that cell penetration may occur at the cell surface in the absence of membrane fusion.辛德毕斯病毒粒子因暴露于低pH值以及与细胞相互作用而发生的构象变化表明,在没有膜融合的情况下,细胞穿透可能发生在细胞表面。
Virology. 2004 Jul 1;324(2):373-86. doi: 10.1016/j.virol.2004.03.046.

引用本文的文献

1
Multimodal Deep Learning for Generating Potential Anti-Dengue Peptides.用于生成潜在抗登革热肽的多模态深度学习
ACS Omega. 2025 Aug 19;10(34):38653-38674. doi: 10.1021/acsomega.5c03510. eCollection 2025 Sep 2.
2
A Japanese encephalitis virus biological clone with an gene point mutation exhibits and attenuation of neurovirulence.一种具有基因点突变的日本脑炎病毒生物学克隆表现出神经毒力的降低和减弱。
J Gen Virol. 2025 Sep;106(9). doi: 10.1099/jgv.0.002137.
3
Aptamer as a therapeutic agent for dengue infections.适体作为登革热感染的治疗剂。
Virol J. 2025 Aug 29;22(1):295. doi: 10.1186/s12985-025-02893-6.
4
Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections.决定反复感染黄病毒属病毒后免疫印记结果的因素。
Front Immunol. 2025 Jul 16;16:1560851. doi: 10.3389/fimmu.2025.1560851. eCollection 2025.
5
Computational insights into flavonoids inhibition of dengue virus envelope protein: ADMET profiling, molecular docking, dynamics, PCA, and end-state free energy calculations.黄酮类化合物对登革病毒包膜蛋白抑制作用的计算洞察:ADMET特性分析、分子对接、动力学、主成分分析及终态自由能计算
PLoS One. 2025 Jul 9;20(7):e0327862. doi: 10.1371/journal.pone.0327862. eCollection 2025.
6
Bioprofiling and vaccine development for Zika virus.寨卡病毒的生物特征分析与疫苗研发
Sci China Life Sci. 2025 Jun 3. doi: 10.1007/s11427-024-2851-4.
7
Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.新型登革热减毒活疫苗候选株的研发:无抗体依赖增强(ADE)作用
Vaccines (Basel). 2025 May 16;13(5):532. doi: 10.3390/vaccines13050532.
8
Detection of DENV in Aedes albopictus during the 2024 sporadic dengue outbreak in Wuhan city, Hubei Province, China.在中国湖北省武汉市2024年登革热散发病例暴发期间白纹伊蚊中登革病毒的检测。
Virol J. 2025 May 24;22(1):163. doi: 10.1186/s12985-025-02763-1.
9
Spatiotemporal dispersion of DENV-1 genotype V in Western Colombia.登革热病毒1型基因型V在哥伦比亚西部的时空扩散
Virus Evol. 2025 Apr 16;11(1):veaf018. doi: 10.1093/ve/veaf018. eCollection 2025.
10
Exploiting host kinases to combat dengue virus infection and disease.利用宿主激酶对抗登革病毒感染及疾病。
Antiviral Res. 2025 May 8;241:106172. doi: 10.1016/j.antiviral.2025.106172.